TCRX - TScan Therapeutics, Inc.

QQQ $ 472.49 $ -2.05 (-0.43 %)

DIA $ 416.26 $ -1.07 (-0.26 %)

SPY $ 562.20 $ -1.67 (-0.3 %)

TLT $ 99.62 $ -1.25 (-1.24 %)

GLD $ 235.53 $ -1.83 (-0.77 %)

Previous Close

$ 5.54

Open

$ 5.51

Bid

$ 5.54 x 189

Ask

-- x --

Day's Range

$ 5.45 - $ 5.70

52 Week Range

$ 2.43 - $ 9.69

Volume

302,216

Average Volume

Market Cap

293.48M

Beta (5Y Monthly)

$ 0.29

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-12-2024	06-30-2024	10-Q
2	05-13-2024	03-31-2024	10-Q
3	03-06-2024	12-31-2023	10-K
4	11-09-2023	09-30-2023	10-Q
5	08-10-2023	06-30-2023	10-Q
6	05-10-2023	03-31-2023	10-Q
7	03-08-2023	12-31-2022	10-K
8	11-09-2022	09-30-2022	10-Q
9	08-10-2022	06-30-2022	10-Q
10	05-12-2022	03-31-2022	10-Q
11	03-09-2022	12-31-2021	10-K
12	11-10-2021	09-30-2021	10-Q
13	08-19-2021	06-30-2021	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Expert Outlook: TScan Therapeutics Through...
08/13/2024 14:00:48

Wedbush Reiterates Outperform on TScan The...
08/13/2024 13:29:12

Wedbush analyst David Nierengarten reiterates TScan Therapeutics (NASDAQ:TCRX) with a Outperform and maintains $10 price tar...

HC Wainwright & Co. Reiterates Buy on TSca...
08/13/2024 12:27:27

HC Wainwright & Co. analyst Andrew Fein reiterates TScan Therapeutics (NASDAQ:TCRX) with a Buy and maintains $15 price t...

Needham Reiterates Buy on TScan Therapeuti...
08/12/2024 17:52:05

Needham analyst Gil Blum reiterates TScan Therapeutics (NASDAQ:TCRX) with a Buy and maintains $11 price target.

TScan Therapeutics' Cash, Cash Equivalents...
08/12/2024 11:21:29

TScan Therapeutics Q2 2024 GAAP EPS $(0.28...
08/12/2024 11:20:33

The Analyst Landscape: 7 Takes On TScan Th...
06/04/2024 15:01:21

HC Wainwright & Co. Reiterates Buy on TSca...
06/04/2024 11:22:04

HC Wainwright & Co. analyst Andrew Fein reiterates TScan Therapeutics (NASDAQ:TCRX) with a Buy and maintains $15 price t...

TScan Therapeutics Says FDA Granted Regene...
05/29/2024 11:05:42

TSC-100 and TSC-101 are the Company's two lead TCR-T therapy candidates for the treatment of heme malignancies. TScan has ...

BTIG Initiates Coverage On TScan Therapeut...
05/16/2024 14:12:19

BTIG analyst Justin Zelin initiates coverage on TScan Therapeutics (NASDAQ:TCRX) with a Buy rating and announces Price Targe...

HC Wainwright & Co. Reiterates Buy on TSca...
05/14/2024 11:23:38

HC Wainwright & Co. analyst Andrew Fein reiterates TScan Therapeutics (NASDAQ:TCRX) with a Buy and maintains $15 price t...

Key Takeaways From TScan Therapeutics Anal...
05/13/2024 12:00:42

TScan Therapeutics' Existing Cash Resource...
05/13/2024 11:07:57

TScan Therapeutics Q1 2024 GAAP EPS $(0.32...
05/13/2024 11:05:35

Needham Reiterates Buy on TScan Therapeuti...
05/13/2024 10:24:23

Needham analyst Gil Blum reiterates TScan Therapeutics (NASDAQ:TCRX) with a Buy and maintains $11 price target.

TScan Therapeutics Doses First Patient In ...
05/09/2024 11:05:16

Unveiling 4 Analyst Insights On TScan Ther...
04/23/2024 18:01:19

Wedbush Reiterates Outperform on TScan The...
04/23/2024 17:17:01

Wedbush analyst David Nierengarten reiterates TScan Therapeutics (NASDAQ:TCRX) with a Outperform and maintains $10 price tar...

TScan Therapeutics Prices Upsized $150M Pu...
04/17/2024 06:13:22

TScan Therapeutics announces pricing of an underwritten public offering of 2,472,581 shares of its voting common stock at a pub...

TScan Therapeutics Reports Launch Of $125M...
04/16/2024 20:26:48

All shares of voting common stock and pre-funded warrants to be sold in the offering will be offered by TScan. The Company inte...